BeOne Medicines AG/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeOne Medicines AG
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Ticker
$ONC
Sector
Primary listing
Employees
12,000
Headquarters
Basel, Switzerland
Website
ONC Metrics
BasicAdvanced
$36bn
72.64
$4.40
0.49
-
Price and volume
Market cap
$36bn
Beta
0.49
52-week high
$385.22
52-week low
$253.95
Average daily volume
365k
Financial strength
Current ratio
3.644
Quick ratio
3.169
Long term debt to equity
38.733
Total debt to equity
43.133
Interest coverage (TTM)
8.15%
Profitability
EBITDA (TTM)
825.389
Gross margin (TTM)
88.31%
Net profit margin (TTM)
8.94%
Operating margin (TTM)
11.95%
Effective tax rate (TTM)
21.70%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
5.96%
Return on equity (TTM)
12.42%
Valuation
Price to earnings (TTM)
72.644
Price to revenue (TTM)
6.136
Price to book
7.47
Price to tangible book (TTM)
7.57
Price to free cash flow (TTM)
32.191
Free cash flow yield (TTM)
3.11%
Free cash flow per share (TTM)
9.938
Growth
Revenue change (TTM)
37.44%
Earnings per share change (TTM)
-218.93%
3-year revenue growth (CAGR)
54.47%
10-year revenue growth (CAGR)
92.74%
3-year earnings per share growth (CAGR)
-38.04%
10-year earnings per share growth (CAGR)
-2.55%
ONC News
AllArticlesVideos
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
Business Wire·11 hours ago
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
Business Wire·6 days ago
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.